U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.23
    -0.13 (-0.25%)
     
  • Gold

    1,828.50
    -1.40 (-0.08%)
     
  • Silver

    24.88
    +0.01 (+0.04%)
     
  • EUR/USD

    1.2088
    -0.0076 (-0.6286%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3595
    -0.0045 (-0.3263%)
     
  • USD/JPY

    103.8380
    -0.0040 (-0.0039%)
     
  • BTC-USD

    36,225.06
    +1,224.40 (+3.50%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.12 (-0.62%)
     

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Has Been Filed Against GoodRx Holdings, Inc. and Encourages Investors to Contact the Firm Before February 16, 2021

·2 min read

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Central District of California on behalf of those who acquired GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) securities during the period from September 23, 2020 through November 16, 2020 (the "Class Period"). Investors have until February 16, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that at the time of the initial public stock offering (the "IPO"), the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Specifically, the complaint alleges that on September 23, 2020, GoodRX completed its IPO. The lawsuit alleges that Defendants timed the IPO before Amazon announced its online pharmaceutical business, making their statements in the Registration Statement and during the Class Period about GoodRx’s competitive position materially false and/or misleading. The lawsuit also alleges that due to these materially false and/or misleading statements, GoodRx Class A common stock traded at artificially inflated prices of more than $64 per share during the Class Period.

Then, just weeks later on November 17, 2020, Amazon announced its Prime Rx plan and a discount card program, which was said to make it "simple for customers to compare prices and purchase medications for home delivery, all in one place." Following this news, GoodRx Class A common stock dropped $10.51 per share, or approximately 23%, from $46.72 per share to $36.21 by close on November 17, 2020.

If you acquired GoodRx securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210101005008/en/

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
investigations@kmllp.com
www.kmllp.com